Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patien… (NCT00347217) | Clinical Trial Compass
CompletedNot Applicable
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Netherlands3,840 participantsStarted 2006-02
Plain-language summary
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The patient has a high risk of a cardiovascular event as defined by the European guidelines.
* The patient is statin-naive (i.e. has not used a statin \> 2 months), or is currently treated with atorvastatin, pravastatin or simvastatin.
* An LDL-C level is known for the statin-naive patient or for the statin used during visit 1.
* It has been decided to start the patient on CRESTOR 5 mg.
* The patient is prepared to give permission to the coded data being made available to AstraZeneca
Exclusion Criteria:
* The patient is known to have complaints of myalgia, myopathy or liver function impairment (including elevated levels of serum transaminases) where there is a causal relationship with the statin treatment.
* Contraindications for treatment with CRESTOR (see 1 B1 text).
* Patients with a family history of dyslipidemias, for instance familiar (combined) hypercholesterolemia